Administration of TRPV4 antagonists improves outcomes in animal models of pulmonary edema, blood-retinal and blood-brain barrier breakdown, and peripheral neuropathy37–39 and the orally bioavailable TRPV4 antagonist GSK2798745 (Fig. 1c) has been safe in clinical trials of pulmonary edema, chronic cough, and diabetic macular edema (NCT02119260, NCT02497937, NCT03372603, and NCT04292912)36,37,40. The gene discussed is TRPV4; the disease is diabetic macular edema.